October 7, 2015
JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ –
TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More
